HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Retailers Take Divergent Paths With CBD Enforcement On Horizon

Executive Summary

Predicted to be worth at least half a billion dollars by the end of the year, the UK's CBD market shows no sign of slowing down. However, regulatory and consumer confusion is distributing the benefits of this growth unevenly, and holding back mass market retailers from leaning in fully, according to a HBW Insight analysis. 

You may also be interested in...

Hiding In Plain Sight: Can TTS Pharma’s ‘Assured Advice’ Unlock UK’s CBD Mass Market?

UK CBD supplier TTS Pharma believes its strategy of establishing partnerhips with local food law enforcement agencies as part of the "assured advice" scheme will unlock the country's cautious mass market. However, without proactive enforcement, the company worries that the UK food authority's legislative efforts to remove sub-standard CBD products from the market, as well as TTS' own efforts to become compliant, will be in vain. 

US FDA Showed ‘Several’ Cards In CBD Bill Comments – CV Sciences’ Duffy MacKay

In itself, the proposed US Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 may be of little consequence. But the FDA’s October comments on the bill were revealing, CV Sciences’ Duffy MacKay says.

State Regulation Of Hemp-Derived Cannabinoids Production, Sales? New York Proposes A Model

New York proposal for packaging and testing hemp-derived cannabinoids could be ‘de facto’ standard for other stat, say attorneys tracking the patchwork of state laws. The proposal sets per-product concentration limits and includes licensing fees for processors and retailers.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts